ReviewVirulence2014
Invasive candidiasis as a cause of sepsis in the critically ill patient.
Review in Virulence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 4 syntheses or guidelines pooled it, 374 citations in OpenAlex.
- Pooled it
- Choosing the Right Antifungal Agent in ICU Patients.Advances in therapy · 2019Pooled it
- The Early Recognition and Management of Sepsis in Sub-Saharan African Adults: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2018Pooled it
- Intensive care medicine research agenda on invasive fungal infection in critically ill patients.Intensive care medicine · 2017Pooled it
- Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing.Microbiology spectrum · 2025Trial
- Development and Validation of a Risk Score for Predicting Invasive Candidiasis in Intensive Care Unit Patients by Incorporating Clinical Risk Factors and Lymphocyte Subtyping.Frontiers in cellular and infection microbiology · 2022Trial
- Observational
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- Integrated Approach for the Discovery of Antifungal and Antibiofilm Agents From Cerrado Plants.Chemistry & biodiversity · 2026Article
- The Prognostic Value of Cardiac Biomarkers in Combination with the SOFA Score for the Evaluation of Sepsis-Related Mortality.Medicina (Kaunas, Lithuania) · 2026Article
- High burden of Candida blankii (syn.Tardiomyces blankii) bloodstream infections among neonates in an intensive care unit in Bangladesh.BMC infectious diseases · 2026Article
- Assessment of skin yeast colonization and its predisposing factors among neonates admitted to the neonatal intensive care unit.BMC infectious diseases · 2026Article
- Knowledge, Attitudes and Practices of Physicians Regarding Antifungal Therapy in Tertiary Care Patients: A Cross-Sectional Survey in Greece.Pathogens (Basel, Switzerland) · 2026Article
- Diagnostic Biomarkers for Invasive Candidiasis: A Clinician-Oriented Review.Journal of fungi (Basel, Switzerland) · 2026Review
- LAMP-Based Detection ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Nationwide epidemiology of candidiasis in Panama, 2010-2020.Scientific reports · 2025Article
- Omics and Multiomics-Based Diagnostics for Invasive Candidiasis: Toward Precision Medicine.Molecular & cellular proteomics : MCP · 2025Review
- Diagnostic Potential of a Recombinant Candida albicans Hyr1 Protein.Mycopathologia · 2025Article
- Article
- Nine-Year Surveillance ofJournal of fungi (Basel, Switzerland) · 2025Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal infections are an increasingly frequent etiology of sepsis in critically ill patients causing substantial morbidity and mortality. Candida species are by far the predominant agent of fungal sepsis accounting for 10% to 15% of health-care associated infections, about 5% of all cases of severe sepsis and septic shock and are the fourth most common bloodstream isolates in the United States. One-third of all episodes of candidemia occur in the intensive care setting. Early diagnosis of invasive candidiasis is critical in order to initiate antifungal agents promptly. Delay in the administration of appropriate therapy increases mortality. Unfortunately, risk factors, clinical and radiological manifestations are quite unspecific and conventional culture methods are suboptimal. Non-culture based methods (such as mannan, anti-mannan, β-d-glucan, and polymerase chain reaction) have emerged but remain investigational or require additional testing in the ICU setting. Few prophylactic or pre-emptive studies have been performed in critically ill patients. They tended to be underpowered and their clinical usefulness remains to be established under most circumstances. The antifungal armamentarium has expanded considerably with the advent of lipid formulations of amphotericin B, the newest triazoles and the echinocandins. Clinical trials have shown that the triazoles and echinocandins are efficacious and well tolerated antifungal therapies. Clinical practice guidelines for the management of invasive candidiasis have been published by the European Society for Clinical Microbiology and Infectious Diseases and the Infectious Diseases Society of North America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.